Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 102 at/kg · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| AMG 102 at 20 mg/kg Dose Level | EXPERIMENTAL | Up to 40 subjects will be treated at 20 mg/kg of AMG 102 Q2W (every 2 weeks) depending upon the stage of the study and number of responses observed. |
| AMG 102 at 10 mg/kg Dose Level | EXPERIMENTAL | Up to 40 subjects will be dosed at 10mg/kg of AMG 102 Q2W (every two weeks) based upon the stage of the study and number of responses observed. |
| Name | Type | Description |
|---|---|---|
| AMG 102 at 10 mg/kg | DRUG | AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks |
| AMG 102 at 20 mg/kg | DRUG | AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks |
Inclusion Criteria: * documented histologically confirmed advanced or metastatic renal cell carcinoma with the primary tumor in place or following nephrectomy * measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques (CT or MRI) or ≥ 10 mm by spiral ...
AMG 102 at/kg is an investigational small molecule being studied for the treatment of advanced renal cell carcinoma and advanced malignant glioma. It is in Phase 2 clinical development and has not been approved by the FDA.
AMG 102 at/kg is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker AMGN. The drug is currently in Phase 2 clinical trials for oncology indications.
AMG 102 at/kg is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. Two Phase 2 studies have been completed, one for advanced renal cell carcinoma and one for advanced malignant glioma.
AMG 102 at/kg has been studied in two completed Phase 2 trials. NCT00422019 evaluated the drug in patients with advanced renal cell carcinoma, and NCT00427440 evaluated it in patients with advanced malignant glioma. Each trial enrolled 61 participants.
Yes, AMG 102 at/kg is a small molecule therapeutic. It is being developed by Amgen Inc. for the treatment of advanced renal cell carcinoma and advanced malignant glioma, and it is currently in Phase 2 clinical trials.